ArticleInternational journal of radiation oncology, biology, physics2016
A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa.
Article in International journal of radiation oncology, biology, physics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- Disease-specific and overall survival for patients with lacrimal gland adenoid cystic carcinoma in recent decades.The British journal of ophthalmology · 2026Article
- Optimizing QACT Frequency in Proton Therapy: Analysis of Standard Guidelines Across Treatment Sites.International journal of particle therapy · 2025Article
- Treatment strategies and prognostic insights for lacrimal gland adenoid cystic carcinoma: a review.Discover oncology · 2025Review
- Long-term outcomes and prognostic factors of eye-preserving treatment with particle beam radiotherapy for orbital malignancies.BMC cancer · 2025Article
- Article
- Advances in treatment of adenoid cystic carcinoma of the lacrimal gland.International journal of ophthalmology · 2025Review
- Review
- Review of recent advances in managing periocular skin malignancies.Frontiers in oncology · 2024Review
- Article
- Epiphora in Treated Lacrimal Drainage System Malignancy Patients - When and Whom to Treat? [Letter].Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Article
- Flourish of Proton and Carbon Ion Radiotherapy in China.Frontiers in oncology · 2022Review
- Roles of skull base surgery and particle radiotherapy for orbital malignant tumors involving the skull base.Laryngoscope investigative otolaryngology · 2021Article
- Primary orbital melanoma: A report of a case and comprehensive review of the literature.Orbit (Amsterdam, Netherlands) · 2021Review
- Proton Beam Therapy in the Treatment of Periorbital Malignancies.International journal of particle therapy · 2021Article
- Proton Therapy in Head and Neck Cancer Treatment: State of the Problem and Development Prospects (Review).Sovremennye tekhnologii v meditsine · 2021Review
- Methodologies to Increase the Level of Evidence of Real-life Proton Therapy in Head and Neck Tumors.International journal of particle therapy · 2021Article
- Clinical Review of Proton Therapy in the Treatment of Unilateral Head and Neck Cancers.International journal of particle therapy · 2021Article
- Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience.International journal of particle therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
purposePostoperative radiation is often indicated in the treatment of malignant epithelial tumors of the orbit and ocular adnexa. We present details of radiation technique and toxicity data after orbit-sparing surgery followed by adjuvant proton radiation therapy. METHODS AND MATERIALS: Twenty patients underwent orbit-sparing surgery followed by proton therapy for newly diagnosed malignant epithelial tumors of the lacrimal gland (n=7), lacrimal sac/nasolacrimal duct (n=10), or eyelid (n=3). Tumor characteristics, treatment details, and visual outcomes were obtained from medical records. Acute and chronic toxicity were prospectively scored using Common Terminology Criteria for Adverse Events version 4.0.
resultsThe median radiation dose was 60 Gy(RBE) (relative biological effectiveness; [range 50-70 Gy]); 11 patients received concurrent chemotherapy. Dose to ipsilateral anterior optic structures was reduced in 13 patients by having them gaze away from the target during treatment. At a median follow-up time of 27.1 months (range 2.6-77.2 months), no patient had experienced local recurrence; 1 had regional and 1 had distant recurrence. Three patients developed chronic grade 3 epiphora, and 3 developed grade 3 exposure keratopathy. Four patients experienced a decrease in visual acuity from baseline but maintained vision sufficient to perform all activities of daily living without difficulty. Patients with grade ≥3 chronic ocular toxicity had higher maximum dose to the ipsilateral cornea (median 46.3 Gy[RBE], range 36.6-52.7 Gy[RBE] vs median 37.4 Gy[RBE], range 9.0-47.3 Gy(RBE); P=.017).
conclusionsOrbit-sparing surgery for epithelial tumors of the orbit and ocular adnexa followed by proton therapy successfully achieved disease control and was well tolerated. No patient required orbital exenteration or enucleation. Chronic grade 3 toxicity was associated with high maximum dose to the cornea. An eye-deviation technique can be used to limit the maximum corneal dose to <35 Gy(RBE).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.